Press Releases Year None20222021202020192018 Nov 07, 2022 Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 03, 2022 Vaxcyte to Present at Upcoming Investor Conferences Oct 28, 2022 Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Oct 26, 2022 Vaxcyte Announces Pricing of $600 Million Public Offering Oct 24, 2022 Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants Oct 24, 2022 Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 Oct 23, 2022 Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Oct 11, 2022 Vaxcyte Expands Executive Leadership Team with Key Appointments Sep 06, 2022 Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older Aug 08, 2022 Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 24
Year None20222021202020192018 Nov 07, 2022 Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 03, 2022 Vaxcyte to Present at Upcoming Investor Conferences Oct 28, 2022 Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Oct 26, 2022 Vaxcyte Announces Pricing of $600 Million Public Offering Oct 24, 2022 Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants Oct 24, 2022 Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 Oct 23, 2022 Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Oct 11, 2022 Vaxcyte Expands Executive Leadership Team with Key Appointments Sep 06, 2022 Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older Aug 08, 2022 Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 24
